Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments.
Bishops Stortford, UK. Dotmatics, the leading provider of scientific informatics solutions and services, announced today that CalciCo Therapeutics has implemented the Dotmatics Platform to manage and analyse their biotherapeutics data, including both chemical and biological information. CalciCo opted to host the platform in the Cloud which efficiently facilitates the handling of all internal research data as well as their networked collaborative engagements.
“We needed to implement a system which would manage our chemistry and biological data. We evaluated several informatics vendors and after careful consideration we chose Dotmatics because they offered flexible and comprehensive solutions with extensive support” said Dr Fraser Murray, Vice President of Biology at CalciCo. “The Cloud hosting of the Dotmatics Platform minimises our IT overheads and gives us peace of mind in relation to data integrity and security. This is particularly important as we work in collaboration with multiple third party organisations.”
CalciCo is a biotechnology company based in Oxford, United Kingdom, which focuses on the development of novel CRAC channel inhibitors. Their research efforts are devoted to developing selective molecules to treat a range of inflammatory and autoimmune conditions where there is clear evidence linking CRAC to human disease. The company has developed proprietary ‘know-how’ comprising novel systems for selective CRAC channel screening and molecule characterisation and they are using the recently implemented Dotmatics Platform to store, analyse and share their distributed research data.
The Dotmatics Platform it is a modular, comprehensive and secure system that underpins all of the informatics solutions provided by Dotmatics. It is a true collaborative environment where researchers can share ideas and discuss results in real time, even if some personnel are in remote locations. Browser is the main hub of the system providing query and reporting capabilities. Studies Notebook enables users to record chemistry, biological and general data in a compliant ELN, and Vortex is the premium data analysis and visualisation tool for big data. Additional modules such as Register, BioRegister and Studies, enable scientists to cover the complete workflow. User-controlled security access across the entire platform ensures both the safekeeping of data as well as integrity.
“We are delighted to welcome CalciCo to our large family of biotechnology customers” said Dr Stephen Gallagher, CEO at Dotmatics. “The number of customers that require end-to-end research informatics systems hosted in the Cloud is growing exponentially. We are in a unique position to deliver great informatics solutions and provide full support services, both of which are vital to the success of many biotech companies.”
Dotmatics is a leading global scientific informatics software and services provider, delivering solutions tailored to the modern, highly collaborative and mobile scientific environments. The company provides solutions to several vertical markets, including the pharmaceutical, biotechnology, academia, food and beverage, oil and gas and agrochemical industries. Dotmatics’ enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. Dotmatics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. Dotmatics solutions are available for local or cloud deployment and they are supported on Microsoft Windows, Mac OS X and Linux. A privately owned company, Dotmatics was founded in 2005 and their headquarters is based south of Cambridge in the UK.